07:45 AM EDT, 08/27/2025 (MT Newswires) -- Amylyx Pharmaceuticals ( AMLX ) said Wednesday it has decided to discontinue the ORION program of AMX0035 in adults with progressive supranuclear palsy as the drug did not show differences compared with placebo on primary or secondary outcomes after 24 weeks.

As a result, the company will discontinue the phase 2b trial and open-label extension, and will not initiate the phase 3 portion of the program.

The company said it will focus on the phase 3 trial of avexitide, with enrollment expected to be completed in 2025 and topline data expected in the first half of 2026.

Amylyx shares were 1.8% lower in premarket trading.